FIELD: chemistry.
SUBSTANCE: invention relates to the unknown hydrochloride of 6-amino-9-[(3R)-1-(2-butinoil)-3-pyrrolidinyl]-7-(4-phenoxyphenyl)-7,9-dihydro-8H-purin-8 and its crystalline form. The compound has the properties of a selective inhibitor of Bruton's tyrosine kinase (Btk) and can be used as an agent for the prophylaxis and / or treatment of diseases associated with Btk involving B-cells and mast cells. Such diseases are allergic, autoimmune, inflammatory, embolic, bone disease or malignancy. The latter may be a non-Hodgkin's lymphoma. Crystals of hydrochloride of 6-amino-9-[(3R)-1-(2-butinoil)-3-pyrrolidinyl]-7-(4-phenoxyphenyl)-7,9-dihydro-8H-purin-8 have in the powder X-ray diffraction, at least, 2 or more peaks at angles 2θ selected from about 8.11, 8.43, 11.57, 12.73, 13.85, 14.20, 14.67, 14.91, 15.94, 16.64, 18.06, 19.74, 20.42, 21.05, 22.57, 23.21, 23.85 and 24.70 degrees. The hydrochloride crystalline form has an endothermic peak at the temperature of 216°C.
EFFECT: said compound has a higher solubility and activity.
10 cl, 4 dwg, 6 tbl, 13 ex
| Title | Year | Author | Number |
|---|---|---|---|
| PURINONE DERIVATIVE HYDROCHLORIDE | 2012 |
|
RU2750538C2 |
| PURINONE DERIVATIVE | 2011 |
|
RU2575340C2 |
| COMBINED THERAPY BASED ON CD20 ANTIBODY AND BTK INHIBITOR | 2014 |
|
RU2727650C2 |
| COMBINATION THERAPY BASED ON ANTI-CD20 ANTIBODY AND BTK INHIBITOR | 2021 |
|
RU2815679C2 |
| PURINONE COMPOUNDS AS KINASE INHIBITORS | 2013 |
|
RU2655388C2 |
| PYRIDINES, PYRIMIDINES AND PYRAZINES AS BRUTON'S TYROSINE KINASE INHIBITORS AND USE THEREOF | 2014 |
|
RU2712220C2 |
| AMINOPIRIDAZINOVE COMPOUNDS AS PROTEINKINASE INHIBITORS | 2014 |
|
RU2674701C2 |
| METHODS FOR TREATMENT OF MALIGNANT TUMOR USING PYRIMIDINE AND PYRIDINE COMPOUNDS WITH BTK INHIBITORY ACTIVITY | 2016 |
|
RU2765154C2 |
| SUBSTITUTED PYRROLO [2,3-D] PYRIDAZIN-4-ONES AND PYRAZOLO [3,4-D] PYRIDAZIN-4-ONES AS PROTEINKINASE INHIBITORS | 2017 |
|
RU2749038C2 |
| COMBINATIONS OF HSP90 INHIBITOR | 2009 |
|
RU2519673C2 |
